Importance of genetics in chronic lymphocytic leukemia

被引：63

作者：

Zenz, Thorsten ^{[1
]}

Mertens, Daniel ^{[1
]}

Doehner, Hartmut ^{[1
]}

Stilgenbauer, Stephan ^{[1
]}

机构：

[1] Univ Ulm, Dept Internal Med 3, D-89081 Ulm, Germany

来源：

BLOOD REVIEWS | 2011年 / 25卷 / 03期

关键词：

CLL; 17p13; deletion; 11q23; P53; 13q14; Prognosis; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; IGVH MUTATION STATUS; CLL PATIENTS; CHROMOSOMAL TRANSLOCATIONS; GENOMIC ABERRATIONS; UNTREATED PATIENTS; CLINICAL-EFFICACY; CLONAL EVOLUTION; TP53; MUTATIONS; POOR-PROGNOSIS;

D O I：

10.1016/j.blre.2011.02.002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recurrent losses or gains of genomic material as well as mutations of key tumor suppressors (ATM and TP53) have been identified in chronic lymphocytic leukemia (CLL). These aberrations are important "drivers" of the disease and some of its clinical characteristics. There is a remarkable heterogeneity in the clinical course between patient subgroups with distinct genetic features. While some mutations are associated with poor outcome (particularly 17p- and TP53 mutation and to a lesser extend 11q-) others are linked to a favorable outcome (13q- as sole aberration; mutated IGHV). Our improved understanding of the clinical course of specific genetic subgroups is beginning to be translated into genotype specific treatment approaches where genetic subgroups (e.g. 17p-) are channeled into separate treatment protocols. This review will summarize the most important genetic aberrations in CLL and how our improved knowledge of the genetic make-up of leukemic cells may translate into improved treatment results. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：131 / 137

页数：7

共 68 条

[1] Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL [J].

Austen, B ;

Powell, JE ;

Alvi, A ;

Edwards, I ;

Hooper, L ;

Starczynski, J ;

Taylor, AMR ;

Fegan, C ;

Moss, P ;

Stankovic, T .

BLOOD, 2005, 106 (09) :3175-3182

[2] Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion [J].

Austen, Belinda ;

Skowronska, Anna ;

Baker, Claire ;

Powell, Judith E. ;

Gardiner, Anne ;

Oscier, David ;

Majid, Aneela ;

Dyer, Martin ;

Siebert, Reiner ;

Taylor, A. Malcolm ;

Moss, Paul A. ;

Stankovic, Tatjana .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (34) :5448-5457

[3] A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease [J].

Best, O. G. ;

Gardiner, A. C. ;

Davis, Z. A. ;

Tracy, I. ;

Ibbotson, R. E. ;

Majid, A. ;

Dyer, M. J. S. ;

Oscier, D. G. .

LEUKEMIA, 2009, 23 (01) :212-214

[4]

BEST OG, 2008, LEUKEMIA

[5]

Byrd JC, 2003, CANCER RES, V63, P36

[6] Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia [J].

Byrd, John C. ;

Lin, Thomas S. ;

Dalton, James T. ;

Wu, Di ;

Phelps, Mitch A. ;

Fischer, Beth ;

Moran, Mollie ;

Blum, Kristie A. ;

Rovin, Brad ;

Brooker-McEldowney, Michelle ;

Broering, Sarah ;

Schaaf, Larry J. ;

Johnson, Amy J. ;

Lucas, David M. ;

Heerema, Nyla A. ;

Lozanski, Gerard ;

Young, Donn C. ;

Suarez, Jose-Ramon ;

Colevas, A. Dimitrios ;

Grever, Michael R. .

BLOOD, 2007, 109 (02) :399-404

[7] Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia [J].

Calin, GA ;

Dumitru, CD ;

Shimizu, M ;

Bichi, R ;

Zupo, S ;

Noch, E ;

Aldler, H ;

Rattan, S ;

Keating, M ;

Rai, K ;

Rassenti, L ;

Kipps, T ;

Negrini, M ;

Bullrich, F ;

Croce, CM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (24) :15524-15529

[8] A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia [J].

Calin, GA ;

Ferracin, M ;

Cimmino, A ;

Di Leva, G ;

Shimizu, M ;

Wojcik, SE ;

Iorio, MV ;

Visone, R ;

Sever, NI ;

Fabbri, M ;

Iuliano, R ;

Palumbo, T ;

Pichiorri, F ;

Roldo, C ;

Garzon, R ;

Sevignani, C ;

Rassenti, L ;

Alder, H ;

Volinia, S ;

Liu, CG ;

Kipps, TJ ;

Negrini, M ;

Croce, CM .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (17) :1793-1801

[9] Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial [J].

Catovsky, D. ;

Richards, S. ;

Matutes, E. ;

Oscier, D. ;

Dyer, M. J. S. ;

FBezares, R. ;

Pettitt, A. R. ;

Hamblin, T. ;

Milligan, D. W. ;

Child, J. A. ;

Hamilton, M. S. ;

Dearden, C. E. ;

Smith, A. G. ;

Bosanquet, A. G. ;

Davis, Z. ;

Brito-Babapulle, V. ;

Else, M. ;

Wade, R. ;

Hillmen, P. .

LANCET, 2007, 370 (9583) :230-239

[10] Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study [J].

Chanan-Khan, Asher ;

Miller, Kena C. ;

Musial, Laurie ;

Lawrence, David ;

Padmanabhan, Swaminathan ;

Takeshita, Kenichi ;

Porter, Carl W. ;

Goodrich, David W. ;

Bernstein, Zale P. ;

Wallace, Paul ;

Spaner, David ;

Mohr, Alice ;

Byrne, Catriona ;

Hernandez-Ilizaliturri, Francisco ;

Chrystal, Cynthia ;

Starostik, Petr ;

Czuczman, Myron S. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) :5343-5349

← 1 2 3 4 5 6 7 →